Showing results (1141-1150 of 1,221) with videos related to
Sort By:
Pageof 123
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2017
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsRuth Ladenstein, Bieke Lambert, Ulrike Pötschger, et al.Contemporary Clinical Trials|May 14, 2025
Assessing the effect of virtual navigation interventions to improve health insurance literacy and decrease financial burden in cancer survivors: The HINT II study protocolElyse R Park, Anne C Kirchhoff, Calli O Mitchell, et al.Frontiers in Immunology|June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K Erbe, Wei Wang, Patrick K Reville, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)M-H Ryu, E Baba, K H Lee, et al.Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapyY-K Kang, M-H Ryu, S H Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.Pageof 123